Streptococcus sinensis endocarditis outside Hong Kong

Emerging Infectious Diseases

Volumn 13, Issue 8, 2007, Pages 1250-1252

  Uçkay, Ilker ^a   Rohner, Peter ^a   Bolivar, Ignacio ^b   Ninet, Béatrice ^a   Djordjevic, Marina ^a   Nobre, Vandack ^a   Garzoni, Christian ^a   Schrenzel, Jacques ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Institut für Angewandte Immunologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADULT; ANAMNESIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; CASE REPORT; CLINICAL FEATURE; ECHOCARDIOGRAPHY; HOSPITALIZATION; HUMAN; MALE; MORTALITY; NUCLEOTIDE SEQUENCE; OPHTHALMOLOGY; PATHOGENESIS; STREPTOCOCCUS;

EID: 34548436107     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1308.080124     Document Type: Article

References (11)

1. Woo PCY, Tam DMW, Leung KW, Lau SKP, Teng JLL, Wong MKM, et al. Streptococcus sinensis sp. nov., a novel species isolated from a patient with infective endocarditis. J Clin Microbiol. 2002;40:805-10.
2. Olsen GJ, Woese CR. Ribosomal RNA: a key to phylogeny. FASEB J. 1993;7:113-23.
3. Woo PCY, Teng JLL, Lau SKP, Yuen KY. Clinical, phenotypic, and genotypic evidence for Streptococcus sinensis as the common ancestor of anginosus and mitis groups of streptococci. Med Hypotheses. 2006;66:345-51.
4. Woo PCY, Teng JLL, Leung KW, Lau SKP, Tse H, Wong BHL, et al. Streptococcus sinensis may react with Lancefield group F antiserum. J Med Microbiol. 2004;53:1083-8.
5. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-8.
6. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA. 1992;267:264-7.
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S9. Wayne (PA): the Committee; 1999.
8. Poyart C, Quesne G, Boumaila C, Trieu-Cuot P. Rapid and accurate species-level identification of coagulase-negative staphylococci by using the sodA gene as a target. J Clin Microbiol. 2001;39:4296-301.
9. Hoshino T, Fujiwara T, Kilian M. Use of phylogenetic and phenotypic analyses to identify nonhemolytic streptococci isolated from patients. J Clin Microbiol. 2005;43:6073-85.
10. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA. 1995;274:1706-13.
11. Francioli P. Antibiotic treatment of streptococcal and enterococcal endocarditis: an overview. Eur Heart J. 1995;16:75-9.